Cardioplegin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412349

CAS#: 68245-15-8

Description: Cardioplegin is a pharmacoplegic agent for producing cardiac standstill in open-heart surgery; contains procaine, magnesium L-asparaginate & sorbitol.

Chemical Structure

img
Cardioplegin
CAS# 68245-15-8
Instruction

Theoretical Analysis

MedKoo Cat#: 412349
Name: Cardioplegin
CAS#: 68245-15-8
Chemical Formula: C21H33ClMgN4O10
Exact Mass: 560.17
Molecular Weight: 561.270
Elemental Analysis: C, 44.94; H, 5.93; Cl, 6.32; Mg, 4.33; N, 9.98; O, 28.51

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cardioplegin; Magnesium aspartate, mixted with procaine hydrochloride

IUPAC/Chemical Name: Magnesate(2-), bis(L-aspartato(2-)-N,O1)-, (T-4)-, dihydrogen, mixt. with 2-(diethylamino)ethyl 4-aminobenzoate monohydrochloride

InChi Key: GRAMCUGYYSXQQQ-UHFFFAOYSA-L

InChi Code: InChI=1S/C13H20N2O2.2C4H7NO4.ClH.Mg/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;2*5-2(4(8)9)1-3(6)7;;/h5-8H,3-4,9-10,14H2,1-2H3;2*2H,1,5H2,(H,6,7)(H,8,9);1H;/q;;;;+2/p-2

SMILES Code: CCN(CCOC(c1ccc(N)cc1)=O)CC.NC(C([O-])=O)CC([O-])=O.NC(C([O-])=O)CC([O-])=O.[H+].[H+].[Mg+2].Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 561.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kalmár P, Bleese N, Döring V, Gercken G, Kirsch U, Lierse W, Pokar H, Polonius MJ, Rodewald G. Induced ischemic cardiac arrest. Clinical and experimental results with magnesium-aspartate-procaine solution (Cardioplegin). J Cardiovasc Surg (Torino). 1975 Sep-Oct;16(5):470-5. PMID: 1194331.

2: Hoffmeister HE, Seboldt H, Seybold-Epting W, Stunkat R. Myokardschutz mit Hypothermie und Cardioplegin bei der Operation angeborener Herzfehler [Myocardial protection utilizing hypothermia and cardioplegin during surgical correction of congenital heart disease (author's transl)]. Thoraxchir Vask Chir. 1978 Apr;26(2):98-103. German. doi: 10.1055/s-0028-1096604. PMID: 653708.

3: Dragoĭchev Ch, Daskalov E, Konstantinov P, Madzharov D. Pŭrvi rezultati ot prilozhenieto kardioplegin pri sŭrdechni operatsii [Initial results of using Cardioplegin in heart operations]. Khirurgiia (Sofiia). 1981;34(1):13-20. Bulgarian. PMID: 7230657.

4: Lorkiewicz Z, Borzycka B, Ponizyński A, Blotna-Filipiak M. Przydatność cardiopleginy do operacji w krazeniu pozaustrojowym [Usefulness of Cardioplegin in surgery with extracorporeal circulation]. Kardiol Pol. 1973;16(4):299-307. Polish. PMID: 4756964.

5: Walpoth B, Fornaro M, von Gossler W, Turina M. Tierexperimentelle Beurteilung des Myokardschutzes mittels Magnesium-asparaginat-procain-Lösung [Animal experiment evaluation of myocardial protection with a magnesium-asparaginate- procaine solution]. Chir Forum Exp Klin Forsch. 1978;(1978):99-102. German. PMID: 752612.

6: Isselhard W, Schorn B, Hügel W, Uekermann U. Comparison of three methods of myocardial protection. Thorac Cardiovasc Surg. 1980 Oct;28(5):329-36. doi: 10.1055/s-2007-1022103. PMID: 6161431.

7: Regensburger D, Hellberg K, Knoll D, Ruschewski W, Schenk HD, Sonntag H, de Vivie R, Wolfram-Donath U. Koronardurchblutung und myokardialer Sauerstoffverbrauch nach künstlichem Herzstillstand [Coronary circulation and myocardial oxygen cosumption after cardioplegic arrest (author's transl)]. Thoraxchir Vask Chir. 1975 Jun;23(3):306-8. German. doi: 10.1055/s-0028-1096969. PMID: 1080609.

8: Isselhard W, Schorn B, Uekermann U, Hügel W. Myokardialer Stoffwechselstatus bei verschiedenen Verfahren zur Einleitung eines reversiblen Herzstillstandes [Myocardial metabolic status in various methods of inducing a reversible heart arrest]. Chir Forum Exp Klin Forsch. 1979:29-32. German. PMID: 456143.

9: Weber DO, Yarnoz MD. Hyperkalemia complicating cardiopulmonary bypass: analysis of risk factors. Ann Thorac Surg. 1982 Oct;34(4):439-45. doi: 10.1016/s0003-4975(10)61407-5. PMID: 7138111.

10: Kugelberg J, Hägerdal M, Carlsson C. Myocardial protection during heart surgery. An experimental evaluation of normothermic and hypothermic cardioplegia. Scand J Thorac Cardiovasc Surg. 1979;13(1):47-52. doi: 10.3109/14017437909101786. PMID: 432573.